Business Context and Reporting Period
Company: GRAIL, Inc. (GRAL)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: GRAIL is a commercial-stage healthcare company focused on multi-cancer early detection (MCED) via its Galleri test. The company operates as a standalone public entity following its spin-off from Illumina, Inc. in June 2024. Galleri is currently marketed as a Laboratory Developed Test (LDT) in the U.S. and is not yet FDA-approved, though a Pre-Market Approval (PMA) application was submitted in January 2026.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $147.2 | $125.6 | +17% |
| Screening Revenue | $138.6 | $108.6 | +28% |
| Development Services Revenue | $8.6 | $17.0 | -49% |
| Net Loss | $(408.4) | $(2,027.0) | -80% (Improvement) |
| Adjusted EBITDA | $(320.6) | $(483.5) | -34% (Improvement) |
| Cash & Cash Equivalents | $249.7 | $214.2 | N/A |
| Short-Term Marketable Securities | $654.7 | $549.2 | N/A |
| Total Liquidity | $904.4 | $763.4 | N/A |
Note: The significant reduction in net loss in 2025 compared to 2024 is largely due to a decrease in goodwill and intangible asset impairments (from $1.42 billion in 2024 to $28 million in 2025).
Material Changes vs. Prior Period
- Revenue Growth: Screening revenue increased 28% driven by a 36% increase in Galleri test volume, partially offset by a 6% decrease in Average Selling Price (ASP). Development services revenue declined 49% due to fewer biopharmaceutical pilot trials.
- Cost Reductions: Operating expenses decreased significantly due to a Restructuring Plan implemented in 2024. Research and Development (R&D) expenses fell 39%, Sales and Marketing (S&M) fell 24%, and General and Administrative (G&A) fell 26%.
- Impairment Charges: Goodwill and intangible asset impairments dropped 98% year-over-year, as the company fully impaired goodwill in 2024 and only recorded a $28 million impairment on in-process R&D in 2025.
- Capital Raises: In 2025, the company raised $311.3 million via a Private Investment in Public Equity (PIPE) and $107.5 million via an At-The-Market (ATM) program.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Regulatory Pathway: A PMA application for Galleri was submitted to the FDA in January 2026. Management believes FDA approval could unlock broad commercial payor coverage. A new law enacted in February 2026 created a Medicare coverage benefit category for MCED tests, with potential coverage initiation as early as January 1, 2029.
- Clinical Data: The company announced topline results from the NHS-Galleri Trial in February 2026. While the primary endpoint (statistically significant reduction in combined Stage 3 and 4 cancers) was not met, the trial showed a substantial reduction in Stage 4 diagnoses and a four-fold increase in cancer detection rates compared to standard screening.
- Strategic Partnerships: A strategic collaboration with Samsung C&T was announced in October 2025 for commercialization in South Korea and other Asian markets, including a pending $110 million equity investment subject to regulatory clearance (CFIUS).
- Liquidity: Management believes existing cash and marketable securities ($904.4 million) are sufficient to fund operations into 2030, though additional financing may be required.
Key Risks and Contingencies
- Regulatory Uncertainty: Galleri is not FDA-approved. The PMA process is lengthy and uncertain. The regulatory landscape for Laboratory Developed Tests (LDTs) remains in flux following a federal court vacating an FDA rule in 2025.
- Reimbursement: Broad reimbursement from Medicare and large commercial payors is not yet secured. The company currently relies on self-insured employers and specific payor contracts.
- Clinical Trial Results: The failure of the NHS-Galleri Trial to meet its primary endpoint may negatively impact perceptions of clinical utility, regulatory approval chances, and commercial adoption.
- Intellectual Property & Royalties: The company owes a perpetual high single-digit royalty (currently suspended until Dec 2026) to Illumina. It also holds licenses from the Chinese University of Hong Kong subject to royalties.
- Supply Chain: GRAIL relies on sole suppliers for critical components: Illumina (sequencers/reagents), Madison Industries (blood collection tubes), and Twist Bioscience (DNA panels).
Investor Verification Checklist
- PMA Status: Verify the current status of the FDA Pre-Market Approval (PMA) application submitted in January 2026 and any requests for additional data.
- Reimbursement Progress: Monitor the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) process for the new MCED benefit category and the timeline for potential coverage initiation.
- Samsung Investment Closing: Confirm the closing of the $110 million Samsung investment and the satisfaction of CFIUS regulatory conditions.
- Intangible Asset Impairment: Review the interim impairment test for long-lived intangible assets (valued at $1.9 billion as of Dec 31, 2025) triggered by the market capitalization decrease following the NHS-Galleri Trial results.
- Royalty Resumption: Track the resumption of royalty payments to Illumina scheduled for December 24, 2026, and its impact on future gross margins.